Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;12(24):21770-21778.
doi: 10.1002/cam4.6743. Epub 2023 Dec 11.

Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival

Olivia Davis  1 , Derek Truong  2 , Silas Day  3 , Manu Pandey  4 , Sami Ibrahimi  4 , Mohamad Khawandanah  4 , Jennifer Holter-Chakrabarty  4 , Adam Asch  4 , Taha Al-Juhaishi  4
Affiliations

Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival

Olivia Davis et al. Cancer Med. 2023 Dec.

Abstract

Introduction: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a rare, highly heterogeneous group of mature T-cell neoplasms that historically has been associated with poor outcomes. We sought to investigate the influence of primary disease site on PTCL-NOS outcomes using a large national cancer registry.

Methods: Baseline clinical and demographic data including primary organ of involvement and Ann Arbor disease stage were extracted from the SEER database. Patients were grouped into nine organ system groups and compared to nodal disease acting as a control. Cox regression models were utilized for adjusted survival analyses.

Results: A total of 3095 patients were identified in the SEER database and included in the final analysis. The median age was 61 and a majority of patients were male (60%) and identified as non-Hispanic white (68%). A plurality of patients had stage IV disease (32%). Lymph nodes and spleen were the most common primary disease sites (67%), while central nervous system was the least common (1%). Patients with early-stage PTCL-NOS of the gastrointestinal/genitourinary systems had worse overall survival [HR = 1.97 (1.50-2.59); p < 0.001] and lymphoma-specific survival [HR = 1.74 (1.26-2.40); p < 0.001] which was statistically significant even after adjusting for other variables. Early-stage PTCL-NOS of the central nervous system also had worse overall survival [HR = 1.90 (1.11-3.27); p = 0.020] and lymphoma-specific survival [HR = 2.11 (1.17-3.80); p = 0.013]. Early-stage PTCL-NOS of the skin had better overall survival [HR = 0.54 (0.42-0.68); p < 0.001] and lymphoma-specific survival [HR = 0.388 (0.28-0.53); p < 0.001] which was statistically significant even after adjustments.

Conclusion: Our findings suggest an association between primary organ involved by PTCL-NOS and both overall and lymphoma-specific survival even after adjusting for common variables. These results warrant validation in future prospective studies.

Keywords: NOS; PTCL; primay lymphoma site; survival outcomes.

PubMed Disclaimer

Conflict of interest statement

O.D. and S.D. declared no competing financial interests.

Figures

FIGURE 1
FIGURE 1
Overall survival for early‐stage (Stage I and II) and late‐stage (Stage III and IV) peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS).
FIGURE 2
FIGURE 2
Peripheral T‐cell lymphoma not otherwise specified (PTCL‐NOS) overall survival according to primary tumor site. All stages of disease are included in this analysis.
FIGURE 3
FIGURE 3
Lymphoma‐specific survival for early‐stage (Stage I and II) PTCL‐NOS.
See this image and copyright information in PMC

References

    1. Oluwasanjo A, Kartan S, Johnson W, et al. Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS). Cancer Treat Res. 2019;176:83‐98. doi:10.1007/978-3-319-99716-2_4 - DOI - PubMed
    1. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T‐cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T‐cell lymphoma project. Blood. 2011;117(12):3402‐3408. doi:10.1182/blood-2010-09-310342 - DOI - PubMed
    1. Zinzani PL, Broccoli A. T‐cell lymphoproliferative disorders. In: Hoffbrand AV, Higgs DR, Mehta AB, eds. Postgraduate Haematology. MDPI; 2015:524‐536.
    1. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720‐1748. doi:10.1038/s41375-022-01620-2 - DOI - PMC - PubMed
    1. Kim J, Cho J, Byeon S, Kim WS, Kim SJ. Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: a systematic review and meta‐analysis. Hematol Oncol. 2021;39(5):664‐673. doi:10.1002/hon.2924 - DOI - PubMed